Use of <font color="red">hormonal_2</font> <font color="red">contraceptives_2</font> and risk of HIV-1 transmission : a prospective cohort study . 
<br>
<br> BACKGROUND <font color="red">Hormonal_2</font> <font color="red">contraceptives_2</font> are used widely but their effects on HIV-1 risk are unclear . We aimed to assess the association between <font color="red">hormonal_2</font> <font color="red">contraceptive_2</font> <font color="red">use_1</font> and risk of HIV-1 acquisition by women and HIV-1 transmission from HIV-1-infected women to their male partners . 
<br> METHODS In this prospective study , we followed up 3790 heterosexual HIV-1-serodiscordant couples participating in two longitudinal studies of HIV-1 incidence in seven African countries . Among <font color="red">injectable_1</font> <font color="red">and_1</font> <font color="red">oral_1</font> <font color="red">hormonal_3</font> <font color="red">contraceptive_3</font> users and non - users , we compared rates of HIV-1 acquisition by women and HIV-1 transmission from women to men . The primary outcome measure was HIV-1 seroconversion . We used Cox proportional hazards regression and marginal structural modelling to assess the effect of <font color="red">contraceptive_1</font> <font color="red">use_1</font> on HIV-1 risk . 
<br> FINDINGS Among 1314 couples in which the HIV-1-seronegative partner was female ( median follow - up 18·0 [ IQR 12·6 - 24·2 ] months ) , rates of HIV-1 acquisition were 6·61 per 100 person - years in women who used <font color="red">hormonal_2</font> <font color="red">contraception_2</font> and 3·78 per 100 person - years in those <font color="red">who_1</font> <font color="red">did_1</font> <font color="red">not_1</font> ( adjusted hazard ratio 1·98 , 95% CI 1·06 - 3·68 , p=0·03 ) . Among 2476 couples in which the HIV-1-seronegative partner was male ( median follow - up 18·7 [ IQR 12·8 - 24·2 ] months ) , rates of HIV-1 transmission from women to men were 2·61 per 100 person - years in couples in which women used <font color="red">hormonal_2</font> <font color="red">contraception_2</font> and 1·51 per 100 person - years in couples in which women <font color="red">did_2</font> <font color="red">not_2</font> <font color="red">use_2</font> <font color="red">hormonal_2</font> <font color="red">contraception_2</font> ( adjusted hazard ratio 1·97 , 95% CI 1·12 - 3·45 , p=0·02 ) . Marginal structural model analyses generated much the same results to the Cox proportional hazards regression . 
<br> INTERPRETATION <font color="red">Women_1</font> <font color="red">should_1</font> <font color="red">be_1</font> <font color="red">counselled_1</font> <font color="red">about_1</font> <font color="red">potentially_1</font> <font color="red">increased_1</font> <font color="red">risk_1</font> <font color="red">of_1</font> <font color="red">HIV-1_1</font> <font color="red">acquisition_1</font> <font color="red">and_1</font> <font color="red">transmission_1</font> <font color="red">with_1</font> <font color="red">hormonal_2</font> <font color="red">contraception_2</font> <font color="red">,_2</font> <font color="red">especially_1</font> <font color="red">injectable_1</font> <font color="red">methods_1</font> <font color="red">,_1</font> <font color="red">and_1</font> <font color="red">about_1</font> <font color="red">the_1</font> <font color="red">importance_1</font> <font color="red">of_1</font> <font color="red">dual_1</font> <font color="red">protection_1</font> <font color="red">with_1</font> <font color="red">condoms_2</font> <font color="red">to_1</font> <font color="red">decrease_1</font> <font color="red">HIV-1_1</font> <font color="red">risk_1</font> <font color="red">._1</font> <font color="red">Non_2</font> <font color="red">-_2</font> <font color="red">hormonal_2</font> <font color="red">or_2</font> <font color="red">low_2</font> <font color="red">-_2</font> <font color="red">dose_2</font> <font color="red">hormonal_2</font> <font color="red">contraceptive_2</font> <font color="red">methods_2</font> should be considered for women with or at - risk for HIV-1 . 
<br> FUNDING US National Institutes of Health and the Bill & Melinda Gates Foundation .